Next‑Gen Amnio-Chorionic Membrane for Enhanced Wound Care is Latest Offering in a Slew of New Products Focused on Increasing Patient Care
LAS VEGAS, NV / ACCESS Newswire / July 1, 2025 / New Horizon Medical Solutions, a leader in advanced biologics and wound care innovation, today announced the launch and addition of AmchoPlast™ to its product portfolio. AmchoPlast is a premium amniotic‑chorionic membrane (amnion – chorion with intermediate layer) product designed to elevate outcomes across surgical and chronic wound indications.
“AmchoPlast strengthens our pipeline of compliant, performance-driven biologics that align with modern wound care protocols,” said Will Hall, CEO, New Horizon Medical Solutions. “This launch reflects our commitment to regenerative medicine, practice optimization, and elevating standards of care.”
Delivering superior benefits and practice optimization
-
Engineered with amiotic-chorionic tissue, AmchoPlast serves as a natural biologic scaffold and barrier, supporting advanced wound care management.
-
Biocompatible and non-immunogenic, the membrane is safe for a diverse patient population and a wide range of wound types.
-
Tri-layer construction provides enhanced handling properties and slower degradation compared to single or bi-layer membranes
Designed for clinical workflow and reimbursement ease
-
Supplied in a sterile, ready-to-use format, AmchoPlast cuts procedural prep time and minimizes infection risk.
-
Shelf-stable at room temperature, it supports versatile storage for hospitals, clinics, or mobile settings.
-
Flexible, easy-to-handle, and available in multiple sizes, it facilitates precise application and reduces product wastage.
“The addition of AmchoPlast cements our portfolio as the most complete in the biologics space,” said D. Christopher Keil, SVP, strategy & corporate development. “We now offer providers and partners the broadest range of choices when selecting regenerative solutions from New Horizon.”
About AmchoPlast™
AmchoPlast, from Cellution Biologics, combines the power of amniotic and chorionic tissues with intermediate layer in a tri-layered construct. Intended to act as a barrier and provide protective coverage from the surrounding environment for acute and chronic wounds such as partial and full thickness wounds, pressure sores/ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (e.g., donor site/grafts, post-laser surgery, post-Mohs surgery, podiatric wounds, wound dehiscence), trauma wounds (e.g., abrasions, lacerations, partial thickness burns, skin tears), and draining wounds. For more information on the product, visit nhmedical.com/products/amchoplast or contact New Horizon Medical Solutions directly at 702-960-2913.
About New Horizon Medical Solutions
New Horizon Medical Solutions is at the forefront of biologic innovation and practice optimization. The company develops regenerative tissue products supported by reimbursement expertise and operational efficiency, empowering providers to improve patient outcomes while maintaining compliance. www.nhmedical.com
—
Media Contact
Julian Rogers, Director of Corporate Marketing
New Horizon Medical Solutions
julian.rogers@nhmedical.com
702-971‑1806
SOURCE: New Horizon Medical Solutions
View the original press release on ACCESS Newswire
